Prelude Therapeutics (PRLD) Depreciation & Amortization (CF) (2019 - 2026)
Prelude Therapeutics (PRLD) reported Depreciation & Amortization (CF) of $391000.0 for Q1 2026, down 10.11% on a YoY basis from $435000.0 in Q1 2025, and down 6.46% sequentially from $418000.0 in Q4 2025.
Prelude Therapeutics (PRLD) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $391000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 10.11% year-over-year to $391000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (down 6.4% YoY), and the FY2025 full-year result was $1.7 million, down 3.44% from the prior year.
- Depreciation & Amortization (CF) slipped to $391000.0 in Q1 2026, from $418000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $489000.0 in Q4 2024 to a low of $278000.0 in Q1 2023.
- A 5-year average of $374529.4 and a median of $391000.0 in 2026 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 91.88% in 2022 and retreated 17.21% in 2023, its largest moves.
- Tracing PRLD's Depreciation & Amortization (CF) over 5 years: stood at $362000.0 in 2022, then declined by 8.56% to $331000.0 in 2023, then surged by 47.73% to $489000.0 in 2024, then decreased by 14.52% to $418000.0 in 2025, then dropped by 6.46% to $391000.0 in 2026.
- Business Quant data shows PRLD's Depreciation & Amortization (CF) at $391000.0 in Q1 2026, $418000.0 in Q4 2025, and $425000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | 391,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 391,000.00 |
| Mar 31, 2026 | 391,000.00 |
| Dec 31, 2025 | 418,000.00 |
| Dec 31, 2025 | 418,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Jun 30, 2025 | 433,000.00 |
| Jun 30, 2025 | 433,000.00 |
| Mar 31, 2025 | 435,000.00 |
| Mar 31, 2025 | 435,000.00 |
| Dec 31, 2024 | 489,000.00 |
| Dec 31, 2024 | 489,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 452,000.00 |
| Jun 30, 2024 | 452,000.00 |
| Mar 31, 2024 | 426,000.00 |
| Mar 31, 2024 | 426,000.00 |
| Dec 31, 2023 | 331,000.00 |
| Dec 31, 2023 | 331,000.00 |